NCT05515445View on ClinicalTrials.gov

Pharmacokinetics of Chiglitazar in Subjects With Hepatic Impairment and Normal Hepatic Function

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 3, 2022

Primary Completion Date

August 23, 2023

Study Completion Date

August 23, 2023

Conditions
Hepatic Impairment
Interventions
DRUG

Chiglitazar

Oral single dose 48 mg

Trial Locations (1)

Unknown

the First Affiliated Hospital of Soochow University, Suzhou

Sponsors
All Listed Sponsors
lead

Chipscreen Biosciences, Ltd.

INDUSTRY